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Summary Forty-one patients receiving remission induction chemotherapy with vincristine, adriamycin and
prednisolone (VAP) for high grade lymphoma or acute lymphoblastic leukaemia were entered into a double
blind, placebo controlled trial of oral acyclovir prophylaxis against herpes simplex virus (HSV) infection. The
dose of acyclovir was 200mg four times daily for the duration of chemotherapy (six weeks). Of the 40
evaluable patients, 20 were randomised to each arm. Prophylactic oral acyclovir significantly reduced the
incidence of clinical HSV infection from 60% on placebo to 5% acyclovir (P<0.001), and the incidence of
viral isolates from 70% on placebo to 5% on acyclovir (P<0.001).
Herpetic infections are common in
immunosuppressed patients with malignant diseases
(Aston et al., 1972; Casazza et al., 1966; Lam et al.,
1981; Meyers et al., 1980; Muller et al., 1972), and
may be life threatening. The oral ulceration and
stomatitis caused by HSV may be associated with
significant morbidity. In the past year eight of 25
(32%) patients with non-Hodgkin's lymphoma,
admitted to our oncology ward with pyrexia when
neutropenic, had virologically confirmed HSV
infections. Intravenous acyclovir has been shown in
randomised, placebo controlled trials to be effective
in the treatment of HSV infection in
immunocompromised patients (Chou et al., 1981;
Mitchell et al., 1981; Wade et al., 1982), and in the
prophylaxis of HSV infection (Hann et al., 1983;
Saral et al. 1981). A report of oral acyclovir
prophylaxis in bone marrow transplant patients has
shown a reduced incidence of HSV in those patients
treated with acyclovir compared with placebo,
without significant toxicity (Gluckman et al. 1983).
The aim of this trial was to evaluate the efficacy
of prophylactic oral acyclovir against HSV
infections in lymphoma and leukaemia patients
receiving remission induction chemotherapy, in a
double blind placebo controlled trial.
Patients and methods
Forty-one patients with high grade non-Hodgkin
lymphoma or acute lymphoblastic leukaemia who
were to receive chemotherapy using the VAP
regimen (Blackledge et al., 1980) (Vincristine 2mg
intravenously weekly for six weeks, Adriamycin
60mgm-2 intravenously fortnightly for three doses,
and oral prednisolone at 50mgday-1 for six weeks)
were eligible for the trial. After obtaining informed
consent patients were randomised to receive
acyclovir 200mg four times daily or placebo tablets
of identical appearance. The tablets commenced on
the first day of chemotherapy and were prescribed
for six weeks.
Patients with non-Hodgkin lymphoma attended
the outpatient clinic for examination and treatment
each week, and those with acute leukaemia were
inpatients for the duration of therapy. Throat swabs
and blood samples for haematology, biochemistry
and acyclovir levels were taken weekly. Blood for
viral serology was taken every three weeks. At each
outpatient visit patients were asked about oral
symptoms and coldsores. Lesions present at the
time of consultation were swabbed for viral culture
and if applicable samples were taken from electron
microscopy. Patients were seen three-four weeks
after cessation of chemotherapy for repeat blood
tests, viral throat swabs and clinical examination.
Virus isolation
Swabs were taken into virus transport medium and
subsequently inoculated into MRC5 human
fibroblast and BK tissue cultures. Cultures were
examined daily for three weeks for cytopathic
effects.
Electron microscopy
Material from lesions was placed upon microscope
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slides and air dried. This was later resuspended in
distilled water and a drop placed on a formvar-
carbon support film on an EM grid. The film was
then stained with 3% PTA and examined under the
electron microscope. Photographs were taken of all
positive samples.
Serology
Sera were tested by standard complement fixation
techniques for antibodies to herpes viruses.
Statistical design and analysis
The design was double blind to prevent patient or
observer bias. The number of patients entered was
chosen to give a high power (90%) of detecting a
real difference in the frequency of herpes simplex
infection of 30-40%, in one-sided binomial tests at
the 5% level of significance. The time to clinical
infection and viral isolation in each trial arm was
compared using a logrank test (Pete et al., 1977),
and results confirmed by Fisher's exact test (Siegel,
1956). Biochemical and haematological values were
compared using analysis of variance.
Results
Forty-one patients were entered into the trial. One
patient, who died on the first day of the study, has
been excluded from the analysis. Two patients were
withdrawn - one refused to take further tablets on
the eighth day of the trial because her mouth was
sore due to candida (acyclovir), the other patient
was withdrawn from treatment because he
developed haemorrhagic cystitis (placebo). These
two patients were included in the analysis until the
Table I Patient characteristics
Acyclovir Placebo Total
Number 20 20 40
Age median 55 51 55
range 17-67 19-75 17-75
Sex male 14 11 25
female 6 9 15
Lymphoma 20 15 35
Leukaemia 0 5 5
HSV titre
< 1/10 at onset 6 4 10
acyclovir was discontinued. The other 38 patients
had all received their full quota of VAP
chemotherapy and acyclovir.
Twenty patients were randomised to acyclovir
and 20 to placebo. Patient characteristics were
similar for each treatment group, except that all five
patients with acute lymphoblastic leukaemia were
randomised to placebo (Table I). Twenty patients
recalled previous HSV infection (seven received
acyclovir).
Only one of the 20 patients in the acyclovir arm
developed clinical infection - the patient described a
coldsore that developed between hospital visits and
lasted three days, whereas 12 of the 20 patients on
placebo developed clinical infection (P<0.001).
(Table II). The time to clinical infection for all
patients was analysed by the logrank method and
the results are shown in Figure 1. Five patients
developed coldsores, three stomatitis, one patient
developed oral ulceration, and another had oral
ulceration, coldsores and pyrexia. Another patient
Table II Number of clinical infections and viral isolates during trial
Acyclovir Placebo P value
Clinical HSV during trial 1/(20 12/20 <0.001
Viral isolates during trial b1/20 14/20 <0.001
Clinical HSV during trial in
patients with HSV titre > 1/10 I.114 10/16 =0.004
Viral isolates during trial in
patients with HSV titre >1/10 b1/14 12/16 <0.001
Clinical HSV during trial
leukaemics excluded a1/20 9/15 <0.001
Viral isolates during trial
leukaemics excluded b1/20 10/15 <0.001
aPatient 35 clinical infection only, cultures not taken as patient was in out-
patient phase.
bPatient 1 asymptomatic, viral culture positive on day one of trial and
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had prolongued pharyngitis, laryngitis and a tongue
ulcer. The final patient had coldsores and pyrexia.
Only one of the 20 patients in the acyclovir arm
had a viral isolate. The patient was asymptomatic
when HSV was isolated from the throat swab on
the first trial day. The virus was not recovered from
the day eight swab. However 14 patients on placebo
had viral isolates during the trial (P<0.001). (Table
II). Four isolates were from coldsores, seven from
throat swabs; one from coldsores and ulcers, one
was from a tongue swab, and one from oral ulcers.
Ten patients presented with HSV titres < 1/10
(Table I). Patients with low titres have been
excluded from other trials because the patients
experience less HSV reactivation (4). If these
patients are excluded there is still a statistically
significant difference between the two groups in the
number of clinical infections and viral isolates
(Table II).
All five patients with acute leukaemia were
randomised to placebo. Three developed clinical
HSV, one of these three had a presenting HSV titre
of < 1/10. Four patients had HSV isolates, one
with a presenting HSV titre of < 1/10. Patients with
leukaemia may be more immunosuppressed than
lymphoma patients. If patients with leukaemia are
excluded from analysis acyclovir still significantly
reduces the incidence of clinical HSV infection and
the number of viral isolates (Table II).
Deaths during the trial
Four patients died during the trial, three were on
acyclovir and one on placebo. Two men died
unexpectedly and coroners post mortems showed
no evidence of lymphoma death being due to
myocardial infarction in one (died day 53) and
small bowel performation in the other (died day
ten). One man died of septicaemia and renal failure
due to lymphoma obstructing the ureters (day ten).
None of these deaths are thought to be acyclovir-
related. The fourth patient was on placebo. She had
c
leukaemia and died of fungal septicaemia despite
treatment with Amphotericin B (day 31).
Infection after cessation ofacyclovir
After the trial period of six weeks there were 16
patients evaluable in the acyclovir group, and 18 in
the placebo group (owing to the four deaths during
the trial and the two withdrawls). Three patients on
acyclovir and four on placebo developed clinical
HSV (three with coldsores, three with oral
ulceration and stomatitis, and one with atypical
pneumonia who was excreting HSV in throat swabs
and whose HSV titres rose from 1/20 to 1/360
during the infection). All these patients had
presenting HSV titres of > 1/10 and had lymphoma.
There were seven patients with viral isolates after
the trial (three in acyclovir arm and four on
placebo). Six of them had clinical infection, and one
had HSV isolated from throat swabs when
asymptomatic. One patient with a healing coldsore
had no viral isolates on EM or culture.
Treatment with intravenous acyclovir
Two leukaemic patients received intravenous
acyclovir during the trial (they continued the
randomised tablets). Both were found to be
receiving placebo when the trial was analysed. One
patient had coldsores, oral ulceration and pyrexia.
He had an initial HSV titre of < 1/10 and this rose
to 40 on day 38. He had five days acyclovir at
5mgkg-' tds. The temperature settled at 48h, the
coldsore scab came off at three days, and the oral
ulcers had healed at 5 days. The other was a lady
with a pyrexia, confusion and eventually coma. She
was on broad spectrum antibiotics and had platelet
support. HSV was isolated in throat swabs just
before the confusion developed. In case this was due
to HSV encephalitis, IV acyclovir was commenced.
There was no response. The patient died of fungal
septicaemia.
HSVserology during the trial
Only six patients had a fourfold rise in titres to
HSV during the trial. Two had clinical infection
and viral isolates, two had viral isolates only (one
with atypical pneumonia may have had a viral
pneumonia), one patient had a coldsore without
viral isolation, and one patient had neither clinical
infection nor viral isolate.
Acyclovir levels
The ED50 for acyclovir is around 0.1 uM for HSV
type 1 (Schaeffer et al., 1978). During the trial
therapeutic acyclovir levels for HSV were obtained.
The peak acyclovir levels (at 1-2h after the last48 H. ANDERSON et al.
dose) were between 1.59-8.63 1M, showing wide
subject variation. There was no evidence of
acyclovir accumulation. The patient who died of
renal failure and septicaemia had acyclovir levels of
8.63 uM (2h post dose) on the day prior to death.
The female patient who developed a coldsore at
home whilst on acyclovir tablets had levels of
0.47MM six hours post dose the visit prior to the
development of the coldsore and 0.71 jiM five hours
post dose the week later.
In vitro testingfor acyclovir resistance
All virus isolated during and after the trial has been
stored frozen. After the trial was analysed isolates
from the four patients in the acyclovir arm have
been tested for acyclovir resistance using a plaque
reduction assay, and none found. (One patient had
isolates during the trial, and three after cessation of
acyclovir). The ED50 values were all less than
0.1IMM, whereas the ED50 for a laboratory selected
thymidine kinase negative mutant resistant to
acyclovir was 7.19yM.
Analysis ofhaematology and biochemistry results
When the acute leukaemia patients are excluded (all
randomised to placebo), the statistical analysis of
haematology and biochemistry results showed that
the only difference between the two groups was that
the mean value of the blood urea was higher in
the acyclovir group on day seven (8.14mmoll-)
compared to the placebo group (6.22mmoll-1)
P=0.047. However, there was no significant
difference for serum creatinine between the two
groups.
Discussion
In this study acyclovir has significantly reduced the
number of clinical infections and viral isolates due
to HSV in patients with high grade non-Hodgkin
lymphoma receiving VAP chemotherapy. There was
no acyclovir associated toxicity during the trial.
One patient, who has withdrawn from the trial
because of haematuria, had previous
cyclophosphamide-induced haematuria. As
haematuria has been described in a patient treated
with acyclovir (A. Clarke, Wellcome Foundation,
personal communication) the patient was
withdrawn from the trial. When the code was
broken, the patient was found to be in the placebo
arm.
In vitro acyclovir resistance was not observed in
the viral isolate from the patient on day one of the
trial, or from the three viral isolates from patients
after the acyclovir was discontinued. This shows
that aquired acyclovir resistance did not occur in
these few patients. The patient who developed a
coldsore between hospital visits had acyclovir levels
above the ED50 for HSV before and after the
episode of infection. As she denied non-compliance
at the time of infection, and the coldsore was not
witnessed one cannot comment on the reason why
infection occurred.
This trial does not answer the question of
whether acyclovir prophylaxis is better than prompt
therapy of HSV infection with oral acyclovir.
Although the latter would cost less, the patient
would still experience the morbidity associated with
infection.
In conclusion, this trial has shown that 200mg
oral acyclovir given six hourly is absorbed from the
gastrointestinal tract, and serum levels adequate to
prevent HSV in most patients are achieved. We
have also confirmed the lack of toxicity shown by
Gluckman et al. (1983). Acyclovir significantly
reduced the incidence of clinical infection and viral
isolates in non-Hodgkin lymphoma patients
undergoing intensive chemotherapy with a VAP
regimen.
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